COMPUTATIONAL ANALYSIS OF PHARMACOKINETICS, BIOACTIVITY AND TOXICITY PROFILING OF SOME SELECTED OVULATION-INDUCTION AGENTS TREATING POLYCYSTIC OVARY SYNDROME (PCOS)

PCOS (Polycystic ovarian syndrome) is a prevalent female endocrine disorder with global occurrence ranging from 6-26%. It accounts for the majority of anovulatory infertility in women of reproductive age due to enlarged ovaries with small cysts formation, which the National Institute of Health has reported as a cause of 30% of infertility cases in females worldwide. Anovulatory infertility is generally treated with ovulation induction therapy using drugs to promote and facilitate ovulation. However, these medications’ varying success rates and numerous adverse effects compel the search for more promising and safer alternatives. In this research study, 10 ovulation induction agents i.e., Tamoxifen, Metformin, Clomiphene, Pioglitazone, Letrozole, Rosiglitazone, Anastrozole, Prednisone, Dexamethasone, and Spironolactone, were selected to analyze their pharmacokinetics, drug-likeness, bioactivity profile, and toxicity profile through the in-silico approach. The results present information about each drug, including its pharmacological competency and level of toxicity. This study may aid in the direction of future research and the development of more effective ovulation-inducing medications.